Rezolute (RZLT) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

RZLT Rezolute

Watchlist

4.860
-0.150-2.99%

Close Nov 21 16:00 ET

4.820
-0.040-0.82%

Post 19:59 ET

281.60MMarket Cap-3826P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Rezolute Granted FDA Orphan Designation for Treatment of Hypoglycemia
TipRanksNov 20 19:25 ET
Is Rezolute, Inc. (RZLT) the Best Multibagger Stock to Buy Heading Into 2025?
Yahoo FinanceNov 16 01:29 ET
We Think Rezolute (NASDAQ:RZLT) Needs To Drive Business Growth Carefully
Yahoo FinanceNov 13 07:41 ET
Maxim Group Maintains Rezolute(RZLT.US) With Buy Rating, Announces Target Price $12
Moomoo NewsNov 9 10:31 ET · Ratings
H.C. Wainwright Maintains Rezolute(RZLT.US) With Buy Rating, Maintains Target Price $14
Moomoo NewsNov 8 11:31 ET · Ratings
Wedbush Maintains Rezolute(RZLT.US) With Buy Rating, Maintains Target Price $12
Moomoo NewsNov 8 07:35 ET · Ratings

Comments

Bigmoney Dreamer

Oct 20 18:07

$Rezolute (RZLT.US)$ 👀 mediocre catalyst

Jaguar8

Sep 9 06:33

NEWS

$Rezolute (RZLT.US)$
FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study
Rezolute, Inc. (Nasdaq: RZLT) announced that the FDA has lifted partial clinical holds on RZ358 (ersodetug), their potential treatment for hypoglycemia caused by congenital hyperinsulinism (HI). This allows the company to include U.S. participants in their ongoing global Phase 3 sunRIZE study. Rezolute plans to begin U.S. enrollm...

Trytosaveabit

Sep 9 06:31

News

$Rezolute (RZLT.US)$ Reuters· 1 min ago
FDA Lifts Partial Clinical Holds on Rz358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study

steven smith38

Aug 5 06:40

$Apple (AAPL.US)$ Update
$Rezolute (RZLT.US)$ Reuters· 6 mins ago
Rezolute Announces FDA Clearance of Ind Application for Phase 3 Registrational Study of Rz358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

steven smith38

Aug 5 06:40

Update
$Rezolute (RZLT.US)$ Reuters· 6 mins ago
Rezolute Announces FDA Clearance of Ind Application for Phase 3 Registrational Study of Rz358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

RZLT Rezolute

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target